Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) has received approval from the National Medical Products Administration for the marketing license of its new drug, SPH3127 tablets, which is a novel oral non-peptide small molecule renin inhibitor for the treatment of primary hypertension [1] Group 1: Drug Approval and Characteristics - The drug name is SPH3127 tablets, with the application acceptance number CXHS2400037 [1] - SPH3127 is designed to directly inhibit renin, counteracting the blood pressure increase caused by the overactivation of the renin-angiotensin-aldosterone system (RAAS) [1] - Preclinical and clinical studies indicate that SPH3127 exhibits stronger renin activity inhibition compared to other drugs targeting the same pathway, demonstrating efficacy in models of hypertension, chronic kidney disease, and inflammatory bowel disease [1] Group 2: Clinical Efficacy and Safety - Completed clinical studies show that SPH3127 has good overall safety and clear antihypertensive efficacy in patients with hypertension [1] - The drug aims to meet the clinical needs of patients with primary hypertension by providing a new treatment option [1] Group 3: Research and Development Investment - To date, approximately 296 million yuan has been invested in the research and development of SPH3127 [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for its new drug, SPH3127 tablets, which are indicated for the treatment of primary hypertension [1] Group 1: Company Developments - Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyin Pharmaceutical Factory, has been granted a drug registration certificate for SPH3127 tablets [1] - The drug is a new generation oral non-peptide small molecule renin inhibitor [1] Group 2: Industry Context - SPH3127 tablets work by directly inhibiting renin, counteracting the blood pressure increase caused by the overactivation of the renin-angiotensin-aldosterone system (RAAS) [1] - The drug is specifically designed for the treatment of primary hypertension [1]

Core Insights - The pharmaceutical distribution industry is a crucial component of the national healthcare system and health industry, significantly impacting public health and safety [1][7] - The industry is experiencing growth due to the implementation of the "two-invoice system" reform and increasing public awareness of healthcare [1][7] Industry Overview - The pharmaceutical distribution market in China is projected to reach a sales volume of 29,470 billion yuan in 2024, with wholesale sales accounting for 22,970 billion yuan (77.94%) and retail sales for 6,500 billion yuan (22.06%) [1][7] - The regional distribution of sales shows that East China accounts for 36.3%, Central South 27.0%, North China 15.2%, Southwest 13.4%, Northeast 4.3%, and Northwest 3.8%, with the top three regions contributing to 78.5% of total sales [9][10] Sales Structure - The sales composition indicates that Western medicine accounts for 70.8% of total sales, followed by traditional Chinese medicine at 14.6%, medical devices at 7.7%, and other categories [9][10] Current State of the Industry - As of the end of 2024, there are 705,400 licensed pharmaceutical businesses in China, including 15,100 wholesale companies and 66,070 retail chain enterprises [3][5] - The total number of retail pharmacies has increased to 683,700, with a notable rise in single retail pharmacies [3][5] Financial Performance - In 2024, the main business income of reported pharmaceutical distribution enterprises reached 22,431 billion yuan, reflecting a 0.8% increase from 2023, while the profit totaled 468 billion yuan with an average gross margin of 7.2% [5][6] Industry Chain - The pharmaceutical distribution industry serves as a critical link in the pharmaceutical supply chain, connecting manufacturers with end-users, including hospitals and pharmacies [11][12] Competitive Landscape - Major players in the pharmaceutical distribution sector include East China Pharmaceutical, Shanghai Pharmaceutical, China National Pharmaceutical Group, and others, with significant revenue contributions from these companies [14][15] Future Development Directions - The industry aims to enhance operational efficiency and inventory management to ensure a stable supply of pharmaceuticals while minimizing financial risks [18][19]

中证港股通央企红利指数（931233.CSI），从港股通范围内，选取中央企业实际控制的分红水平稳定且 股息率较高的50只上市公司股票进行打包；截至12月9日，该指数近1年股息率是6.71%，高于同期10年 期国债收益率4.84%，港股央企红利ETF（513910）是跟踪该指数规模最大的投资标的。 注：除净日，就是一只股票开始"剔除"即将派发的股息（红利）的日期。从这一天起，买入该股票的投 资者，将无法享受到本次派发的股息。 简单投资，加点红利！ 每日经济新闻 恒生中国内地企业高股息率指数（HSMCHYI.HI），筛选打包在港上市，内地公司中的高股息股票； 截至12月9日，该指数近1年股息率是6.19%，高于同期10年期国债收益率4.31%，恒生红利ETF （159726）是跟踪该指数的唯一ETF。 非标普港股通低波红利港币指数（SPAHLVHP.SPI）筛选打包在港上市的50只高股息低波动股票，港股 通红利低波ETF（159118）是跟踪该指数综合费率最低的一只ETF。 上海医药：每股0.13215港元；除净日：2025-12-30，派息日期：2026-02-06；恒生行业：药品分销；非 中证港股通央企红利指 ...

证券代码：601607 证券简称：上海医药 公告编号：临2025-113 上海医药集团股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东大会召开的时间：2025年12月9日 ■ (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 2025年第二次临时股东大会（以下简称"本次股东大会"）由本公司董事会召集、董事长杨秋华先生主 持，采用现场与网络投票（网络投票仅针对A股股东）相结合的表决方式，本公司股东代表、监事代表 及律师于股东会上担任监票人。本公司股东会议的召集、召开和表决方式符合《中华人民共和国公司 法》等法律法规和《上海医药集团股份有限公司章程》的有关规定。 (五)公司董事、监事和董事会秘书的出席情况 1、公司在任董事9人，出席5人，董事张文学先生、董明先生，独立董事顾朝阳先生、霍文逊先生因其 他公务未能出席本次股东大会。 (二)股东大会召开的地点：中国上海市黄浦区太仓路2 ...

Core Viewpoint - The Chinese government will ban the production of mercury-containing thermometers and blood pressure monitors starting January 1, 2026, marking the end of mercury thermometers in the market [1]. Company Impact - Companies such as Yuyue Medical (002223.SZ) and Jiuan Medical (002432.SZ) have indicated that the impact of this ban on their business will be minimal, as they primarily focus on electronic products and have a very small volume of mercury thermometer and blood pressure monitor sales [1][5]. - Jiuan Medical stated that their main revenue source comes from reagent kits, particularly in the U.S. market, and they are not traditional manufacturers of thermometers [1]. Market Observations - There has been a noticeable increase in demand for mercury thermometers on e-commerce platforms, leading to stock shortages, while electronic and glass thermometers are more readily available [2]. - In physical pharmacies, staff reported that they have sold out of mercury thermometers due to increased demand, especially during the flu season, but they still offer electronic and infrared thermometers at significantly higher prices [4]. Industry Transition - Some medical companies have already begun transitioning away from mercury thermometers in anticipation of the ban, although they have not received formal notifications regarding the prohibition of sales [5]. - The market is expected to shift towards electronic and infrared thermometers, which are perceived as more convenient, especially for families with young children [4].

上海医药（601607）(02607)公布，将于2026年2月6日派发中期股息每10股1.3215港元。 ...

Core Viewpoint - Shanghai Pharmaceuticals (02607) announced a mid-term dividend of HKD 1.3215 per 10 shares, to be distributed on February 6, 2026 [1] Company Summary - The company is set to distribute a mid-term dividend, indicating a commitment to returning value to shareholders [1]

第一章 總則 第一條 為強化董事會決策功能，做到事前審計、專業審計，確保董事會對 總裁層級的有效監督，完善公司治理結構，根據《中華人民共和國公司法》、《上 市公司獨立董事管理辦法》、《上市公司治理準則》、《香港聯合交易所有限公 司證券上市規則》（"《聯交所上市規則》"）、《上海證券交易所股票上市規 則》、《上海證券交易所上市公司自律監管指引第 1 號——規範運作》、《公司 章程》、《董事會議事規則》及其他有關規定，公司特設立董事會審計委員會（"審 計委員會"），並制定本實施細則（"細則"）。 第二條 審計委員會是董事會下設的專門工作機構，主要負責公司與外部審 計機構的關係，審閱公司的財務資料，監管公司財務申報制度、風險管理及內部 監控系統，以及審議監督公司環境、社會及管治事宜。 第二章 人員組成 第三條 審計委員會成員由三名獨立董事組成，其中至少有一名為專業會計 人士。 第四條 審計委員會委員由董事長、二分之一（1/2）以上獨立董事或者全 體董事的三分之一（1/3）以上提名，並由董事會選舉產生。 第五條 審計委員會設召集人一（1）名，由委員中的專業會計人士擔任， 負責主持委員會工作；召集人在委員內選舉，並報請 ...

上海醫藥集團股份有限公司 (於中華人民共和國註冊成立的股份有限公司) 章 程 （2025 年 12 月修訂） 經 2016 年 8 月 25 日六屆二次董事會修訂通過，並經 2016 年 10 月 20 日召開的 2016 年第一次臨時股 東大會審議批准。 經 2017 年 10 月 30 日六屆十一次董事會、2018 年 3 月 23 日六屆十四次董事會修訂通過，並經 2018 年 6 月 26 日召開的 2017 年度股東大會審議批准。 經 2019 年 4 月 26 日六屆二十三次董事會、2019 年 5 月 27 日六屆二十五次董事會修訂通過，並經 2019 年 6 月 27 日召開的 2018 年度股東大會審議批准。 經 2020 年 4 月 28 日七屆十一次董事會審議通過，並經 2020 年 6 月 23 日召開的 2019 年年度股東大 會、2020 年第一次 A 股類別股東大會及 2020 年第一次 H 股類別股東大會審議批准。 經 2022 年 8 月 29 日七屆三十三次董事會及 2023 年 6 月 13 日七屆三十九次董事會修訂通過，並經 2023 年 6 月 29 日召開的 202 ...